secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268154
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

LB Pharmaceuticals Reports Q3 2025 Results and Provides Trial Updates
---------------------------------------------------------------------

- Net loss narrowed to $3.6M in Q3 2025 from $14.2M in Q3 2024.
- Raised $327.8M in upsized IPO at $15.00 per share in September 2025.
- Plans to initiate Phase 3 schizophrenia trial with ~460 patients in Q1 2026, topline expected H2 2027.
- Appointed William Kane and Rekha Hemrajani to Board, James Rawls as SVP of Regulatory Affairs.
- Cash position of $314.5M expected to fund operations into Q2 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312525268154/0001193125-25-268154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312525268154/d84790d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer